Neoadjuvant aumolertinib monotherapy for EGFR-mutant lung squamous cell carcinoma: a case report.

ABSTRACT:

Background

Lung cancer is the malignant tumor with high incidence and mortality in China, and more than 30% of non-small cell lung cancer (NSCLC) patients are in the locally advanced stage at the first-time diagnosis. Currently, neoadjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) combined with radical surgery is effective in the treatment of unresectable stage III EGFR-mutated NSCLC (NSCLCm), and related studies are gradually increasing. But the feasibility of neoadjuvant EGFR-TKI combined with radical surgery for unresectable stage III EGFR-mutant lung squamous cell carcinoma (LUSQm) remains controversial.

Case description

This report presented a successful case of neoadjuvant target-therapy with aumolertinib, the third-generation EGFR-TKI, com

SUBMITTER: Liu Y 

PROVIDER: S-EPMC11225048 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature